

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/787,986	06/27/2001	Richard James Lewis	14438	1227
75	90 08/22/2002			
Scully Scott Murphy & Presser			EXAMINER	
400 Garden City Plaza Garden City, NY 11530			KAM, CHIH MIN	
			ART UNIT	PAPER NUMBER
			1653	1
			DATE MAILED: 08/22/2002	16

Please find below and/or attached an Office communication concerning this application or proceeding.

		Applicati n N .	Applicant(s)			
Office Acti n Summary		09/787,986	LEWIS ET AL.			
		Examin r	Art Unit			
		Chih-Min Kam	1653			
Peri d f	The MAILING DATE of this communication appears n the c ver she t with the c rresp ndence address Peri df r Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status						
1)[Responsive to communication(s) filed on					
2a) <u></u>	This action is FINAL . 2b) Thi	s action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disp sit	on of Claims	,				
4)⊠ Claim(s) <u>1-27</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5)□	Claim(s) is/are allowed.					
6)□	6) Claim(s) is/are rejected.					
7)	Claim(s) is/are objected to.					
8) Claim(s) 1-27 are subject to restriction and/or election requirement.						
Application Papers						
9)☐ The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Pri rity under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) All b) Some * c) None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Acknowledgment is made of a claim for domestic priority under 35 0.5.C. 99 120 and/or 121. Attachment(s)						
1) Notic	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal Pa	PTO-413) Paper No(s) atent Application (PTO-152)			

Application/Control Number: 09/787,986

Art Unit: 1653

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions, which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

- 1. Group I, claims 1-10 and 16-27, drawn to an isolated χ -conotoxin peptide, a composition comprising a χ -conotoxin peptide, a chimeric peptide comprising a segment of sequence of χ -conotoxin peptide and a segment of sequence of another biologically active peptide, a use of χ -conotoxin peptide in the manufacture of a medicament, and a method for the treatment or prophylaxis of urinary or cardiovascular diseases, or mood disorders or for the treatment of pain or inflammation, comprising administering to a mammal a χ -conotoxin peptide, classified in class 514, subclasses 14, class 530, subclass 327, and class 435, subclass 69.7.
- 2. Group II, claims 12, 13 and 15, drawn to an isolated nucleic acid comprising a sequence of nucelotides encoding or complementary to a sequence encoding a χ -conotoxin peptide, and a genetic construct comprising a vector and a nucleic acid capable of encoding a χ -conotoxin peptide, classified in class 536, subclass 23.5, and class 435, subclass 320.1.
- 3. Group III, claim 14, drawn to a monoclonal or polyclonal antibody specific to a χ -conotoxin peptide, classified in class 530, subclass 387.1.

Application/Control Number: 09/787,986

Art Unit: 1653

4. Group IV, claim 11, drawn to a use of χ -conotoxin peptide in a receptor binding assay to test the activity of a molecule as an inhibitor of neuronal noradrenaline transporter, classified in class 514, subclasses 14, class 530, subclass 327.

The claims of these groups are directed to different inventions, which are not linked to form a single general concept. The claims in the different groups do not have in common the same or corresponding technical features. In particular, each group is directed to distinct chemical entities and/or methods, which use different materials and produce different effects. Accordingly, the claims are not so linked by a special technical feature within the meaning of PCT Rule 13.2 so as to form a single inventive concept and lack of unity is deemed proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement is traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Chih-Min Kam whose telephone number is (703) 308-9437. The examiner can normally be reached on 8.00-4:30, Mon-Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low, Ph. D. can be reached on (703) 308-2923. The fax phone numbers

Art Unit: 1653

for the organization where this application or proceeding is assigned are (703) 308-0294 for regular communications and (703) 308-4227 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Chih-Min Kam, Ph. D. CMK Patent Examiner

August 20, 2002